Daiichi gets $1.35B up front from AZ in antibody-drug conjugate deal

AstraZeneca will pay Daiichi Sankyo $1.35 billion up front to bolster one of the four platforms of its oncology unit, ADCs.

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NYSE:AZN) announced Friday that they will jointly develop and commercialize the Japanese pharma’s antibody-drug conjugate fam-trastuzumab deruxtecan (DS-8201) worldwide, except in Japan.

Daiichi Sankyo is eligible for $5.55

Read the full 573 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers